Occasional Constipation Is Allowed, With a Condition

what did fda's proposed rule originally say about constipation?

FDA's original 2000 proposal put constipation on the disease-claim side of the line, full stop.

The draft rule listed 'alleviates constipation,' unqualified, among the phrases that would convert a supplement into an unapproved drug — no distinction for how often the symptom struck, how mild it was, or how the copy was hedged. That draft treated a claim about occasional gas the same way it treated a claim about arthritis: as evidence the seller intended the product to treat disease. Industry comment pushed back hard enough that FDA reopened the record specifically to reconsider it.

This isn't an isolated reversal. FDA drew a near-identical line for heartburn, sleep and several other everyday complaints in the same rulemaking, and in nearly every case the word that survives the rewrite is the same modifier — see Occasional or Chronic: The Word That Decides for how the pattern holds across the other symptom categories FDA addressed.

what is the exact permitted phrasing in the final preamble?

The permitted phrase, verbatim, is 'for relief of occasional constipation.' FDA says so directly in the Federal Register preamble: 'For relief of occasional constipation' would therefore not be considered a disease claim under the rule.

We read the full preamble rather than a secondhand summary of it, and the reversal is unambiguous. FDA reopened the comment period in July 1999 specifically to ask whether constipation claims should be treated differently, then concluded that constipation 'has a variety of causes, many of them unrelated to disease.' The concession is narrow but real: FDA moved a whole symptom category off the disease-claim list because commenters convinced the agency the original line was too blunt.

That's the entire safe-harbor sentence. Nothing else in the preamble expands it, and no later FDA guidance broadens the wording past 'occasional.'

what carve-out does the labeling have to make clear?

The carve-out requires your labeling to say, in effect, that the product isn't meant for chronic constipation — not implicitly, but as an affirmative statement FDA can point to.

The same asymmetric structure shows up elsewhere in the rulemaking — a mild, common version of a symptom is fine to name, the severe or persistent version isn't, and the label has to draw that line itself. Absentmindedness Is Allowed. Memory Loss Is Not. walks through the same mechanism for cognitive claims.

• State plainly that the product is for occasional constipation only, not chronic or ongoing use
• Avoid duration language — "daily," "ongoing," "long-term relief" — that undercuts the word "occasional" doing the legal work
• Place the carve-out near the claim itself, not buried in a footer or a separate FAQ page
• Carry the standard DSHEA disclaimer alongside it too, since the carve-out doesn't replace that separate labeling duty

why does chronic constipation read as a disease claim?

Chronic constipation reads as a disease claim because FDA ties it directly to serious underlying conditions, not because a copywriter picked an unlucky adjective. The agency wrote that constipation 'can also, however, be a symptom of such serious diseases as bowel obstruction and irritable bowel syndrome,' and that link is what converts persistence into pathology.

The symptom, not your copy's tone, is what triggers the rule.

That rule is 21 CFR 101.93(g)(2)(ii), FDA's signs-and-symptoms provision, and it reaches lay language as readily as clinical terms. We couldn't find a warning letter that turns specifically on the phrase "chronic constipation," as opposed to letters bundling constipation into broader digestive-symptom lists — confirming a claim-specific enforcement pattern here would take a full-text search of FDA's letter database filtered to that exact phrase, and we haven't run it.

when does a regularity product stop being a supplement at all?

A regularity product stops being a supplement the moment it's formulated and labeled as an OTC (over-the-counter) stimulant laxative rather than a dietary ingredient carrying a structure/function claim. Senna, bisacodyl and similar actives sit inside FDA's laxative drug monograph (the rulebook of pre-approved OTC uses), and a product built around one of them — carrying a Drug Facts panel (the standardized OTC label layout) and a treatment indication — is regulated as a drug from the first bottle.

That reclassification pulls in cGMP, FDA's manufacturing-quality rulebook for drugs, in place of the lighter rules written for dietary supplements. FDA has already said the word itself isn't the trap: 'the term "laxative" will not be considered a disease claim under the final rule,' as long as the rest of the label doesn't reach for chronic-use language.

what cgmp exposure comes with a senna or stimulant laxative formula?

A senna or stimulant-laxative formula carries drug-grade manufacturing exposure, not just a stricter claims review, once the product is regulated as an OTC laxative rather than a supplement.

FDA's warning letter to Health Plus Inc., issued December 29, 2021, shows what that exposure actually looks like in practice, and it has almost nothing to do with the sales copy. FDA cited cGMP violations for the company's Super Colon Cleanse Stimulant Laxative, an over-the-counter drug product, noting that the firm 'changed the formulation of your Super Colon Cleanse Stimulant Laxative in December 2017' and flagging inadequate process validation, method validation and stability data behind that change. No landing page, testimonial or disease claim shows up anywhere in the letter. The entire citation is about whether the company could document that its manufacturing process reliably produced what the label promised, which is the finished-pharmaceutical standard under 21 CFR Parts 210 and 211, not the dietary supplement standard under Part 111 that most regularity brands are actually built to run.

We checked the citation language itself rather than assume the word "laxative" triggered it — the letter never quotes marketing copy at all, only the validation records behind a formulation change.

how should a regularity funnel be structured to keep the carve-out visible?

A regularity funnel keeps the carve-out visible by stating the non-chronic limitation in the same block of text as the benefit claim, not in a disclaimer page a reader has to click through. If your landing page ever pairs "daily" or "ongoing" with "relief," you've likely undone the occasional framing that makes the claim legal in the first place.

Here's the part most operators get backwards: going fully OTC-drug, with a monograph indication and a Drug Facts panel, is arguably the safer structure for a serious regularity product, not the riskier one. The disease question is already settled by the monograph, and the exposure that remains — validation records, stability data, batch documentation — is inside your control in a way ambiguous structure/function copy never is, as Health Plus's own citation shows. Either path still needs FTC-level substantiation, since the FTC's Health Products Compliance Guidance applies its randomized-controlled-trial standard regardless of which FDA claim category you land in.

The same 'occasional' logic governs the adjacent heartburn niche, covered in 'Occasional' Is the Word Holding Heartburn Copy Up.

It's worth checking your refund language against the same standard, since a guarantee tied to a specific cure timeline is its own separate claim — see Your Money-Back Guarantee Wording Is a Claim.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Supplement Quiz Funnel Examples That Convert (2026), Cortisol Supplement Ads: The Stress-Belly Angle Wave, Offers Targeting GLP-1 Users: The Side-Effect Economy, Best Nutra Affiliate Networks: Ranked by Offer Depth, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.